Username:

Password:


 
ABOUT HIV PREVENTION TREATMENT NEWS COMMUNITY ABOUT US EN ESPAÑOL POZ MAGAZINE

 

Back to home » News & Views » Treatment News


 

July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007

emailrssprint

April 28, 2008

Better Antibiotics for Second-Line PCP Treatment

A combination of two oral antibiotics is more effective than the commonly used, yet side effect-prone, intravenous pentamidine for people who’ve failed their first AIDS-related pneumonia regimen, according to the authors of a new study published in the May 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS). Data supporting the use of clindamycin and primaquine is promising news for the roughly 10 percent of patients whose first course of treatment for Pneumcystis jirovecii pneumonia (PCP) doesn’t work.

Intravenous pentamidine is known for a range of serious side effects, including kidney toxicity, low blood pressure and low white blood cell count, and has been shown less effective as treatment for PCP than the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX), commonly known as Bactrim or Septra. For this reason, pentamidine is typically recommended only as second-line therapy for those who don’t respond effectively to their initial treatment choice, or as first-line treatment for people who cannot tolerate TMP-SMX. There are alternatives to pentamidine, but there has been little research to show how effective they may be in treating people who fail their first PCP regimen.

Thomas Benfield, MD, DMSci, from the Department of Infectious Diseases at Hvidovre University Hospital in Copenhagen, Denmark, and his colleagues conducted an analysis of 29 published studies, plus an additional 82 case reports from three European cities. In all, they were able to study the outcomes of 468 second-line PCP treatment episodes.

Benfield’s team found intravenous pentamidine was effective 44 percent of the time in curing cases of PCP in people who’d failed their first treatment. However, the cure rate was far higher (73 percent) in people who took clindamycin and primaquine, which are also less likely to cause serious side effects than pentamidine.

Benfield’s group recommends that clindamycin-primaquine now be used as second-line treatment in people with PCP who fail on TMP-SMX, or who cannot tolerate TMP-SMX.

NEW! Scroll down to comment on this story.

emailrssprint


Name: (2-50 characters)
Email: (will not show)
City: (optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]







Michelle



Glenn



Hilary





[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy